Tier 2 — strong

Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects

Charles la Porte, Nha Voduc, Guijun Zhang, Isabelle Seguin, Danielle Tardiff, Neera Singhal, D William Cameron
Clinical pharmacokinetics 2010 49(7):449

Bibliography

PubMed
PMID 20528005
DOI
10.2165/11531820-000000000-00000
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignOpen-label within-subject steady-state pharmacokinetic study
ModelHuman intervention research
Sample8 healthy adults
InterventionTrans-resveratrol 2,000 mg twice daily under food, alcohol, and quercetin 500 mg twice-daily conditions
DurationTwo-period repeated-dose study
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2010, this source examined safety, interactions and special populations. Design: Open-label within-subject steady-state pharmacokinetic study. Sample/model: 8 healthy adults. The exposure or intervention was Trans-resveratrol 2,000 mg twice daily under food, alcohol, and quercetin 500 mg twice-daily conditions. Follow-up or treatment period: Two-period repeated-dose study.

Quercetin did not increase resveratrol exposure; a high-fat breakfast reduced it. Diarrhea was frequent during the high-dose resveratrol study.

Small resveratrol-centered experiment. Adverse effects cannot be assigned to quercetin alone, and this does not establish a general synergy between the compounds.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Resveratrol Together: Evidence and Practical Choices. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin did not increase resveratrol exposure; a high-fat breakfast reduced it.
  • Diarrhea was frequent during the high-dose resveratrol study.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Trans-resveratrol 2,000 mg twice daily under food, alcohol, and quercetin 500 mg twice-daily conditions; Two-period repeated-dose study.

What this study can and cannot tell us

  • Small resveratrol-centered experiment. Adverse effects cannot be assigned to quercetin alone, and this does not establish a general synergy between the compounds.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Meilan K Han et al. · BMJ open respiratory research · 2020
Tier 2
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin
Antonella Riva et al. · Minerva cardioangiologica · 2019

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology